Personalis Inc (PSNL) - Total Assets
Based on the latest financial reports, Personalis Inc (PSNL) holds total assets worth $325.39 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Personalis Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Personalis Inc - Total Assets Trend (2017–2025)
This chart illustrates how Personalis Inc's total assets have evolved over time, based on quarterly financial data. Check Personalis Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Personalis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Personalis Inc's total assets of $325.39 Million consist of 80.2% current assets and 19.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.2% |
| Accounts Receivable | $16.20 Million | 4.9% |
| Inventory | $6.14 Million | 1.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Personalis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Personalis Inc (PSNL) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Personalis Inc's current assets represent 80.2% of total assets in 2025, an increase from 79.6% in 2017.
- Cash Position: Cash and equivalents constituted 37.2% of total assets in 2025, down from 67.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.9% of total assets.
Personalis Inc Competitors by Total Assets
Key competitors of Personalis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Personalis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.61 | 6.91 | 10.39 |
| Quick Ratio | 6.44 | 6.76 | 10.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $219.15 Million | $176.53 Million | $320.22 Million |
Personalis Inc - Advanced Valuation Insights
This section examines the relationship between Personalis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 1.87 |
| Asset Growth Rate (YoY) | 23.6% |
| Total Assets | $334.16 Million |
| Market Capitalization | $626.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Personalis Inc's assets above their book value (1.87x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Personalis Inc's assets grew by 23.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Personalis Inc (2017–2025)
The table below shows the annual total assets of Personalis Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $334.16 Million | +23.64% |
| 2024-12-31 | $270.27 Million | +20.07% |
| 2023-12-31 | $225.10 Million | -23.10% |
| 2022-12-31 | $292.70 Million | -26.18% |
| 2021-12-31 | $396.53 Million | +61.95% |
| 2020-12-31 | $244.84 Million | +55.66% |
| 2019-12-31 | $157.29 Million | +277.47% |
| 2018-12-31 | $41.67 Million | +24.15% |
| 2017-12-31 | $33.56 Million | -- |
About Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole tran… Read more